NCT07394530 Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS
| NCT ID | NCT07394530 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hanoi General Hospital (Vietnam) |
| Condition | Polycystic Ovary Syndrome (PCOS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2026-01-20 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the outcomes of two ovarian stimulation protocols used in in vitro fertilization (IVF): the progestin-primed ovarian stimulation (PPOS) protocol and the GnRH antagonist protocol.
Eligibility Criteria
Inclusion Criteria: * Women aged 18-40 years * Diagnosed with polycystic ovary syndrome (PCOS) according to the modified Rotterdam criteria (2004) (≥2 of 3: oligo/anovulation, hyperandrogenism, or polycystic ovarian morphology on ultrasound) * Indicated for in vitro fertilization (IVF) due to PCOS alone or PCOS with other infertility factors (e.g., tubal factor, previous failed IUI) * Eligible for controlled ovarian stimulation for IVF * Husband/partner with normal sperm parameters or mild to moderate oligoasthenoteratozoospermia (OAT) * Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: * Uterine abnormalities that may impair implantation or pregnancy outcomes, including congenital uterine malformations, large fibroids distorting the uterine cavity, adenomyosis, or severe intrauterine pathology. * History of major ovarian or uterine surgery affecting ovarian reserve or uterine structure (e.g., ovarian cystectomy, endometriosis surgery, myomectomy, unilateral oophorectomy) * History of recurrent pregnancy loss (≥3 spontaneous miscarriages) * Known chromosomal abnormalities in either partner * Inability to adhere to study protocol or follow-up procedures
Contact & Investigator
Phuong Duy Nguyen, MD, MS
PRINCIPAL INVESTIGATOR
Hanoi General Hospital
Frequently Asked Questions
Who can join the NCT07394530 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Polycystic Ovary Syndrome (PCOS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07394530 currently recruiting?
Yes, NCT07394530 is actively recruiting participants. Contact the research team at nguyenduyphuongncs44@gmail.com for enrollment information.
Where is the NCT07394530 trial being conducted?
This trial is being conducted at Hanoi, Vietnam.
Who is sponsoring the NCT07394530 clinical trial?
NCT07394530 is sponsored by Hanoi General Hospital (Vietnam). The principal investigator is Phuong Duy Nguyen, MD, MS at Hanoi General Hospital. The trial plans to enroll 400 participants.